IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published 3 weeks
Medical Professional
Differentiating ropeginterferon as the “modern” interferon
What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)
Rahul Banerjee, MD
Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)
Gabriela Hobbs, MD
Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)
Eytan Stein, MD
Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)
Wade Iams, MD
What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)
Gabriela Hobbs, MD
Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)
Eytan Stein, MD